Variant hemoglobin phenotypes, including sickle cell trait and hemoglobin C trait, may be associated with resistance to treatment with erythropoietin-stimulating agents (ESAs) among African Americans with end-stage renal disease (ESRD).
Hemodialysis (HD) patients hospitalized for infections receive significantly higher amounts of replacement IV iron therapy and cumulative iron dose, according to findings presented here at the National Kidney Foundation 2010 Spring Clinical Meetings.
High ESA and IV iron use for mild anemia raises mortality risk
The FDA has approved a risk management program to inform health care providers and their patients about the risks of erythropoiesis-stimulating agents (ESAs), which include epoetin alfa and darbepoetin alfa.
After 36 months of follow-up, patients were 26% less likely to die or start dialysis, study finds.
SAN DIEGO—Anemia, CKD, and microalbuminuria are each independently associated with an increased risk of all-cause mortality, regardless of the presence of cardiovascular disease (CVD).
Researchers also show that administration of erythropoietin is followed by marked reductions in circulating hepcidin.
Investigators believe elevated levels of endogenous soluble erythropoietin receptors may have a role.
Heart failure and diabetes could make reported risks clinically undetectable.
Ascorbic acid may be effective in managing anemia in hemodialysis (HD) patients, according to a recent meta-analysis by Canadian investigators.
